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Background: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder among 
reproductive-aged women. It is known to be associated with cardiovascular diseases. The aim of this 
study was to determine and compare the echocardiographic data of patients according to the phenotypes 
of PCOS.
Methods: This study included 113 patients with PCOS and 52 controls. Patients were classified into 
four potential PCOS phenotypes. Laboratory analyses and echocardiographic measurements were 
performed. Left ventricular mass was calculated by using Devereux formula and was indexed to body 
surface area.
Results: Phenotype-1 PCOS patients had significantly higher homeostasis model assessment — insu-
lin resistance (HOMA-IR) (p = 0.023), free testosterone (p < 0.001), LDL cholesterol levels (p < 0.001) 
and free androgen index (p < 0.001) compared with the control group. There were significant differences 
between groups regarding the septal thickness, posterior wall thickness, Left ventricular ejection frac-
tion, E/A ratio and left ventricular mass index (for all, p < 0.05). PCOS patients with phenotype 1 and 
2 had significantly higher left ventricular mass index than the control group (p < 0.001). In univariate 
and multivariate analyses, PCOS phenotype, modified Ferriman-Gallwey Score and estradiol were 
found as variables, which independently could affect the left ventricular mass index. 
Conclusions: This study showed that women in their twenties who specifically fulfilled criteria for 
PCOS phenotype-1 according to the Rotterdam criteria, had higher left ventricular mass index and 
decreased E/A ratio, which might be suggestive of early stage diastolic dysfunction. (Cariol J 2017; 24, 
4: 364–373)
Key words: polycystic ovary syndrome, echocardiography, diastolic dysfunction, left 
ventricular mass
Introduction
Polycystic ovary syndrome (PCOS) is a hetero-
geneous endocrine disorder among reproductive-
aged women with an estimated prevalence of 5% 
to 10% [1]. Despite the ongoing debate on the 
diagnostic criteria, there is a wide consensus that 
the PCOS is diagnosed when two of the three fol-
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lowing features are present; irregular menstrual 
cycles due to oligo- or anovulation, evidence of 
biochemical or clinical androgen excess and poly-
cystic ovaries [2]. Introduction of these broadened 
criteria resulted in a considerable increase in the 
prevalence of PCOS [3]. 
PCOS is known to be associated with a cluster 
of adverse cardiovascular (CV) features such as 
obesity, insulin resistance, hypertension and con-
sequently an increased risk of CV disease (CVD) 
[4, 5]. But due to heterogeneous clinical expression 
of PCOS, data on the association of PCOS with 
CVD have been inconsistent. Better definition of 
sub-phenotypes related with increased CV risk 
is required. Currently there are no consensus 
guidelines regarding screening for CVD in patients 
with PCOS. Considering that risk is not same in 
all PCOS patients, it remains to be elucidated to 
what extent women presenting with PCOS face 
increased long-term CV risk. Previous studies 
have not assessed whether the overall PCOS 
phenotype or the individual components of PCOS 
are associated with the development of subclini-
cal CVD. Identification of the early asymptomatic 
impairment of left ventricular (LV) function may be 
an important indicator in preventing a progression 
to overt heart disease. 
The aim of this study was to determine and 
compare the echocardiographic data of patients 
among the sub-phenotypes of PCOS with those of 
healthy subjects by using conventional echocardio-
graphic methods and tissue Doppler imaging. Thus, 
the aim was to identify which PCOS sub-groups are 
strongly associated with increased CV risk. 
Methods 
Patient population 
This cross-sectional observational study was 
conducted by Cardiology and Obstetrics and Gyne-
cology Department of our institute. A total of 113 
patients with PCOS and 52 controls were enrolled in 
this study. Study groups were matched with respect 
to age and body mass index (BMI). Subjects were 
informed regarding the purpose of the study and 
provided written informed consent. Local Ethics 
Committee of our institute approved the protocol 
of  the study. 
Definitions 
PCOS was diagnosed according to the Rot-
terdam criteria in the presence of at least two of 
the following three features: oligo- or anovulation 
(ANOV), clinical and/or biochemical hyperandro-
genism (HA), and polycystic ovarian morphology 
in one or both ovaries (PCOM) [2]. Afterwards, 
women diagnosed with PCOS were classified into 
one of four potential PCOS phenotypes: 
 — phenotype 1: HA + ANOV + PCOM;
 — phenotype 2: HA + ANOV;
 — phenotype 3: HA + PCOM;
 — phenotype 4: ANOV + PCOM.
The following exclusion criteria were used in 
the selection of patients and controls: any CV dis-
order (including hypertension), diabetes mellitus, 
thyroid and renal diseases, pregnancy or breast-
feeding, hyperprolactinaemia, Cushing’s syndrome, 
congenital adrenal hyperplasia, history of any 
neoplastic disorder, chronic alcohol consumption 
and current or previous use of glucocorticoids, oral 
contraceptives, ovulation induction agents, anti-
androgens, other hormones, anti-hypertensive, 
anti-diabetic drugs. Women who could not be 
assigned to a specific PCOS phenotype were also 
excluded from the study. Control subjects were 
chosen among healthy women with no clinical or 
biochemical evidence of hyperandrogenaemia or 
hirsutism, regular menstrual cycles and normal 
ovaries on ultrasonography scan. 
The screening began with a thorough de-
tailed history inquiry. Subsequently, anthropometric 
measurements were performed, including height, 
weight, BMI, systolic and diastolic blood pressure 
(SBP, DBP), waist circumference (measured midway 
between the arcus costae and anterior superior iliac 
spine), hip circumference (measured at the level 
of the anterior superior iliac spine), and the mea-
surement of hirsutism with the use of the modified 
Ferriman-Gallwey Score (m-FGS). The waist-to-hip 
ratio (WHR) was also calculated. Arterial blood pres-
sure was measured using a mercury sphygmoma-
nometer; the mean of three measurements of SBP 
and DBP was taken while the subjects were sitting 
after a 10-min rest. BMI was calculated as weight in 
kilograms divided by the square of height in meters 
(kg/m2). Metabolic syndrome was defined as hav-
ing at least three of the following three features: 
increased waist circumference (> 88 cm), increased 
blood pressure (SBP ≥ 135 mm Hg, DBP mm Hg 
≥ 85, or treatment for hypertension), increased 
fasting glucose (≥ 100 mg/dL or taking medications 
for diabetes), increased triglycerides (≥ 150 mg/dL), 
and decreased  high density lipoprotein cholesterol 
(< 40 mg/dL). Oligo-anovulation was defined as 
oligomenorrhea (mean bleeding interval 35–182 
days in last six menstrual bleeds) or amenorrhea 
(absence of menstrual bleeding for > 182 days). 
Clinical and biochemical hyperandrogenism were 
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obtained from the four-chamber view by placing a 
tissue Doppler sample volume. The Nyquist limit 
was adjusted to 15–20 cm/s with minimum gain 
and low-filter settings. Early (Em) and late (Am) 
diastolic velocity was obtained. Pulsed-wave tis-
sue Doppler recordings of the lateral portion of the 
mitral annulus were used for the assessment of 
peak early diastolic mitral annular velocity (Em). 
The ratio of the mitral inflow early diastolic veloc-
ity to the peak early diastolic annular velocity (E/
Em) was computed to estimate LV filling pressure.
Statistical analyses
Baseline variables were expressed as means 
with standard deviation or numbers with percentage. 
Multiple imputation and other statistical analyses 
were performed with the use of SPSS statistics 
version 20.0. Group comparisons were performed 
by one-way ANOVA with Tukey’s post hoc test. 
To determine the independent variables likely to 
affect the LVMI, a multivariate linear regression 
analysis was performed with a backward selection 
process including parameters, which were clinically 
important, found significant in univariate correlati-
on analysis and significantly differed between the 
groups. Differences were considered statistically 
significant when the p value was < 0.05. 
Results 
Demographic and clinical results 
Clinical characteristics and laboratory find-
ings of patients and the control group are shown 
in Tables 1 and 2. PCOS population involved 
41 (36%) patients with phenotype-1 (ANOV + HA 
+ PCO), 20 (17%) patients with phenotype-2 
(ANOV + HA), 25 (22%) patients with pheno-
type-3 (HA + PCO) and 27 patients (23%) with 
phenotype-4 (ANOV + PCO). The four-phenotype 
groups and the control group were similar in terms 
of fasting glucose, fasting insulin, and presence of 
metabolic syndrome, FSH, estradiol, prolactin, tri-
glycerides, total testosterone, androstenedion, and 
DHEAS. There were differences between groups 
regarding age, SBP and DBP, BMI, WHR, m-FGS, 
HOMA-IR, LDL levels, LH/FSH ratio, free testos-
terone, SHBG and FAI. Compared with the control 
group all four phenotypes of PCOS were noted to 
have higher SBP and DBP (p < 0.001). Subjects 
from both phenotype-1 and phenotype-3 PCOS had 
higher BMI than the control group (p = 0.020). 
Phenotype-1 PCOS patients had significantly 
higher HOMA-IR (2.66 ± 1.61 vs. 1.91 ± 0.89; 
p = 0.023), free testosterone (2.75 ± 1.40 vs. 1.68 
defined as m-FGS ≥ 8, and/or a free androgen index 
(FAI: [Total testosterone (nmol/L)/sex hormone-
-binding globulin (nmol/L) × 100]) > 4.5 [6]. PCOM 
was defined as ≥ 12 follicles measuring 2–9 mm in 
diameter in at least one ovary, or increased ovar-
ian volume (> 10 mL). Baseline venous blood was 
sampled in the morning after an overnight fast. The 
following endocrinologic and metabolic laboratory 
parameters were selected for comparative analysis 
between PCOS phenotypes and the control groups: 
follicle stimulating hormone (FSH), luteinizing 
hormone (LH), estradiol (E2), free testosterone, 
total testosterone, dehydroepiandrosterone sulfate 
(DHEA S), sex hormone-binding globulin (SHBG), 
prolactin, insulin, glucose, total cholesterol (TC), 
triglycerides (TG), and high-density lipoprotein 
cholesterol (HDL-C), low-density lipoprotein cho-
lesterol (LDL-C). Insulin resistance was assessed 
with the use of the homeostasis model assessment 
(HOMA-IR: [fasting glucose (mg/dL) × fasting 
insulin (μIU/mL)]/405) [7]. The cut-off value for 
HOMA-IR was taken as 2.7.
Echocardiographic evaluation
After a 15-min resting period, the patients 
were examined in the left lateral decubitus posi-
tion with a Vivid S5 (GE Healthcare, Norway). 
Complete 2D, color, pulsed and continuous-wave 
Doppler examination were performed according 
to the standard techniques. Measurements of 
LV, left atrial dimension and wall thickness were 
performed according to the recommendations of 
the American Society of Echocardiography (ASE)
guidelines using parasternal long- and short-axis 
views [8]. LV mass (LVM) was calculated from 
2 -dimensional echocardiographic measurements by 
using Devereux formula: LVM = 1.04 × [(IVST 
+ PWT + LVDd) – (LVDd)3] – 13.6 and was indexed 
to body surface area [9]. Left ventricular hyper-
trophy (LVH) was defined as a LVM index (LVMI) 
greater than 95 g/m2, which is an upper limit of nor-
mal LVM in women. Categorizations of LVH either 
concentric or eccentric hypertrophy were done 
according to recommendations of the ASE guide-
lines [8]. A modified Simpson’s biplane method was 
applied to calculate LV ejection fraction (LVEF). 
Trans-mitral pulsed-wave Doppler velocity were 
recorded from the apical four-chamber view with 
Doppler sample placed between the tips of the 
mitral leaflets. Early (E) and late (A) diastolic wave 
velocity, E/A ratio were measured from the mitral 
inflow profile. The mitral annular myocardial veloc-
ity was obtained from the two- and four-chamber 
view and tricuspid annular myocardial velocity was 
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± 0.52; p < 0.001), LDL levels (117.14 ± 21.27 vs. 
93.51 ± 24.06; p < 0.001) and FAI (5.08 ± 4.69 vs. 
1.57 ± 1.38; p < 0.001) compared with the control 
group whereas other phenotypes and control group 
were similar. 
Echocardiographic results 
The echocardiographic data of patients and 
the control group included in the study are shown 
in Table 3. The four phenotypes and the control 
group did not differ regarding LV dimensions, 
end--diastolic volume, end-systolic volume, E peak 
rate, Em peak rate and E/Em ratio. But there were 
significant differences between groups regarding 
the septal thickness, posterior wall thickness, 
LVEF, E/A ratio and LVMI. Although the E/A ra-
tio was significantly decreased in all phenotypes 
compared to the control group, this decrease was 
prominent in phenotype-1 PCOS. Regarding the 
LVEF, subjects with phenotype-1 PCOS differed 
significantly compared to the control and pheno-
types 2–4 groups (p = 0.001). Significant differ-
ences were also found between PCOS patients 
and control group regarding the presence of LVH 
(p = 0.003). Subjects with phenotype 1 and 2 PCOS 
had significantly higher LVMI values than the 
control group (p < 0.001), while subjects with 
phenotype 3 and 4 did not have a higher LVMI 
compared with the control group (Fig. 1). 
All parameters evaluated in this study were 
entered for univariate analysis, and only param-
eters correlated significantly with LVMI were 
specified in the table. In univariate correlation 
analysis, PCOS phenotype, m-FGS, E2 and LDL 
level correlated significantly with LVMI (p < 0.05, 
for all) (Table 4). Subsequently, a backward multi-
variate linear regression analysis was performed 
to determine the independent variables likely to 
affect the LVMI, which were clinically important, 
found significant in univariate correlation analysis 
and significantly differed between groups. Variables 
entered into the multivariate linear regression 
analysis were age, FAI, SBP, presence of metabolic 
syndrome, PCOS phenotype, m-FGS, estradiol 
(E2), HOMA-IR and LDL-C. Multivariate analysis 
showed that phenotype (p < 0.001), m-FGS 
(p < 0.001), and E2 (p = 0.029) were independently 
associated with LVMI (Table 4). 
Discussion
This study demonstrated that the presence 
of PCOS phenotype-1 and -2 in young women, 
is clearly associated with an increased LVMI and 
decreased E/A ratio compared to the control group. 
Table 4. Univariate and multivariate analysis to determine the variables likely to affect the left  
ventricular mass index.
Variable Univariate analysis Multivariate analysis
r p Unstandardized 
Coefficient b
95% CI p
PCOS phenotype –0.277 < 0.001 –4.221 –5.569–2.874 < 0.001
m-FGS –0.164 0.035 –1.527 –2.177– –0.877 < 0.001
E2 –0.166 0.033 –0.148 –0.280– –0.015 0.029
LDL-C 0.190 0.014 0.060 –0.019–0.139 0.137 
CI — confidence interval; PCOS — polycystic ovary syndrome; m-FGS — modified Ferriman-Gallwey Score; E2 — estradiol; LDL-C — low-
density lipoprotein cholesterol. Parameters included in the multivariate analysis were: age, free androgen index (FAI), systolic blood pressure, 
presence of metabolic syndrome, PCOS phenotype, m-FGS, E2, homeostasis model assessment-insulin resistance (HOMA-IR) and LDL-C
Figure 1. Left ventricular (LV) mass index of four phe-
notypes and the control group; ANOV — oligo- or an-
ovulation; HA — hyperandrogenism; PCOM — poly-
cystic ovarian morphology; PCOS — polycystic ovary 
syndrome.
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These echocardiographic findings might indicate 
the early stage of cardiac diastolic dysfunction 
and/or abnormalities in the filling phase of the left 
ventricle. 
It is a established fact that diastolic dysfunc-
tion might be one of the first echocardiographic 
abnormalities in patients with hypertension and 
atherosclerotic heart disease [10]. There is com-
pelling evidence that patients with PCOS have 
increased CV risk compared with age-matched 
controls. Thus, this association was not surpris-
ing because of the higher incidence of diabetes 
mellitus, obesity, impaired glucose tolerance and 
metabolic syndrome in this patient population [11]. 
Because CV involvement was seen subsequently 
with PCOS, ventricular diastolic dysfunction may 
be an early indicator of impending heart disease. 
A group of PCOS related factors could po-
tentially contribute to LV dysfunction in PCOS 
including hormonal aberrations, obesity, endothe-
lial dysfunction and insulin resistance (IR) [12]. 
Obesity has been estimated to affect more than 
50% of women with PCOS [13]. The pathophysi-
ologic contribution of obesity to LV dysfunction 
includes chronic overload with LVH increased 
oxygen consumption, lipotoxicity associated car-
diac steatosis, myocardial fibrosis and overproduc-
tion of cardio-inhibitory cytokines [14]. Although 
our patient population and control group subjects 
were not obese, BMI was significantly higher in 
phenotype-1 group. This finding supports that 
being overweight may be one of the contributors 
of impaired LV relaxation in patients with PCOS.
Insulin resistance is a common abnormality in 
patients with PCOS [15]. But approximately 50% 
of obese women with PCOS may not have docu-
mented IR by intensive testing. [13]. IR may lead to 
increased sodium retention with subsequent blood 
volume increase, myocyte growth and fibrosis and 
activation of the sympathetic nervous system that 
causes unfavorable effects on CV system [14, 16]. 
An association was also demonstrated between IR 
and coexisting vascular endothelial dysfunction and 
impaired mitochondrial oxidative metabolism that 
may impair the myocardial functions [17]. In this 
study by Victor et al. [17], authors concluded that 
the inflammatory state that affects the endothelial 
function is related to IR in PCOS patients. The pre-
sent findings showed that only phenotype-1 PCOS 
group had significantly higher HOMA-IR compared 
to control subjects. This finding is consistent with 
the previous reports that show relationship be-
tween LV diastolic dysfunction and IR [14, 16, 18].
In this study, phenotype-1, which can be defined 
as a severe form of PCOS was significantly differed 
from the control group regarding the variables such 
as LVMI, HOMA-IR, FAI, free testosterone and LDL 
levels. Higher FAI and free testosterone levels in 
this group were consistent with hyperandrogenism. 
Evidence from recent studies have demonstrated that 
hyperandrogenic PCOS phenotype encompasses the 
patients with the most unfavorable cardiometabolic 
profiles [19, 20]. Therefore, this study is consistent 
with previous reports and hyperandrogenism might 
be one of the contributors of impaired LV diastolic 
function in PCOS patients.
Previous studies investigating PCOS and 
conventional echocardiographic parameters are 
limited to small case control studies and the results 
are not consistent due to underlying differences 
in defining the PCOS population [21–25]. Some 
previous studies reported no significant differences 
in certain echocardiographic measures of cardiac 
function between PCOS patients and healthy sub-
jects including ejection fraction, mitral E/A ratio, 
and tissue Doppler parameters [22, 25]. In a study, 
Tiras et al. [24] reported evidence of diastolic 
dysfunction in patients with PCOS based on flow 
parameters such as isovolumetric relaxation time 
(IVRT), atrial filling time, and pre-ejection time. 
However, they found no differences in E/A ratio, 
left atrium diameter index or LVMI [24]. Orio et 
al. [21] also reported a 40% higher mean LVMI in 
PCOS women compared with age and BMI matched 
controls. 
Increased LVMI usually occurs as a result 
of stressors such as hypertension or increased 
wall stress in LV cavity. It is often an early sign 
of diastolic dysfunction, or failure of the heart to 
relax and fill during diastole [26]. In this study, it 
was found that mean E/A values and LVM indices 
of each group reside within the normal ranges as 
depicted in Table 3. However when compared with 
the healthy controls significant decrease in E/A 
ratio and increase in LVMI was observed in pheno-
type 1 and 2. Besides LVH was more prevalent in 
phenotype 1 and 2. Despite the normal mean val-
ues, this finding suggests cardiac remodeling is tak-
ing place in early years of life in those phenotypes 
and may lead to overt clinical cardiac dysfunction 
in the feature. In this study PCOS phenotype was 
found as an independent predictor of LVMI. PCOS 
is related with increased blood pressure but LV 
structural changes in PCOS is shown to be inde-
pendent from blood pressure changes [21, 27]. In 
the present study, blood pressure levels were com-
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parable among each PCOS phenotype and healthy 
controls. What causes LV structural changes in 
PCOS remains to be elucidated. These results 
are consistent with the previous reports showing 
higher risk for CVD in PCOS subjects [28, 29]. 
The E/A ratio is also one of the most widely used 
parameters for determining diastolic dysfunction. 
Reduced E wave velocity and increased A wave 
velocity (or a decreased E/A ratio) is suggestive of 
impaired relaxation pattern related with diastolic 
dysfunction. Consistent with our results Yarali et 
al. [30] reported that PCOS patients had decreased 
mitral E/A ratio and shorter IVRT compared to 
control group. Nevertheless, there are some other 
studies, which reported no differences in mitral 
E, A velocities and E/A ratio between the PCOS 
patients and controls [25].
Considering that risk is not the same in all 
patients, it remains to be elucidated that the extent 
to which hormonal and metabolic abnormalities 
of PCOS might contribute to cardiac dysfunction 
and which phenotype of women presenting with 
PCOS face increased long-term CV risk. In com-
parison with previous studies, this study compares 
PCOS patients with different phenotypes, as well 
as its individual components such as HA, ANOV 
and PCOM. The present study demonstrated that 
women especially, who fulfilled criteria for PCOS 
phenotype-1 showed evidence for both higher LVMI 
and decreased E/A ratio, which might suggest the 
early stage of cardiac diastolic dysfunction. 
Limitations of this study
The main limitation of this study was that it was 
based on the analysis in a single center and involved 
a small number of women with PCOS and its sub-
phenotypes. The definitions of oligomenorrhea and 
hirsutism were based on self-report. However, self-
reported hirsutism and oligomenorrhea have been 
shown to correlate with both hormone levels and 
sonographic polycystic ovaries supporting their va-
lidity in the diagnosis of PCOS [31]. Other methods 
such as 3D based formula and 2D based formula for 
assessing LVM have some advantages over classical 
method including the ability to take more accurate 
measurements and higher reproducibility. Because 
of a wealth of published data and ease of use, espe-
cially in larger populations with previously dem-
onstrated prognostic value a classical method was 
used. Isovolumic relaxation time and deceleration 
time would be helpful during assessment of diastolic 
function of left ventricle. Unfortunately, we did not 
measure these parameters. Because this is a cross-
sectional study, a causal relationship between PCOS 
phenotypes and early adverse cardiac remodeling 
could not be concluded. This study, however, can 
be considered a preliminary effort in understanding 
the links between PCOS and heart disease. Large-
scale studies are needed to understand and validate 
results herein. 
Conclusions 
This study showed that women in their twen-
ties who especially fulfilled criteria for PCOS 
phenotype-1 according to the Rotterdam criteria, 
presented with higher LVMI, reduced E wave ve-
locity and increased A wave velocity (or a relatively 
decreased E/A ratio compared to healthy controls) 
could be suggestive of impaired relaxation pattern 
related with diastolic dysfunction. Early detection 
of asymptomatic impairment in myocardial relax-
ation in these patients may provide appropriate 
strategy for prevention of CVD. Additional large 
scale prospective studies with detailed PCOS 
phenotypic data and longer follow-up periods are 
needed to confirm these results. 
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